Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-036683
Filing Date
2025-03-10
Accepted
2025-03-10 19:56:53
Documents
1
Period of Report
2025-03-06

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 4108
  Complete submission text file 0000950170-25-036683.txt   5782
Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics, Inc. (Issuer) CIK: 0001650648 (see all company filings)

EIN.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O 4D MOLECULAR THERAPEUTICS INC. 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address
Kamal Fariborz (Reporting) CIK: 0001834020 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39782 | Film No.: 25725462